Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Adenosine Triphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 9/20 | 0.76 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.76 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.76 |
| ▸ | SRC | P12931 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.76 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.76 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.76 |
| ▸ | LDHA | P00338 | 1/20 | 0.76 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.76 |
| ▸ | FBP1 | P09467 | 1/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.76 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.76 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.76 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Triphosphate SCHEMBL30786396 | 1.00 | P2RY1 (0.76) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL27531093 | 0.99 | P2RY1 (0.75) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL30522306 | 0.99 | P2RY1 (0.78) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL29352529 | 0.99 | P2RY1 (0.78) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL28359 | 0.99 | P2RY1 (0.78) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL3040417 | 0.99 | P2RY1 (0.78) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL27783353 | 0.98 | P2RY1 (0.76) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL4594623 | 0.98 | P2RY1 (0.76) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL3498805 | 0.98 | P2RY1 (0.76) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL29760430 | 0.98 | P2RY1 (0.76) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304884-B2 | Photo-cleavable surfactants | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240293426-A1 | INTRAVENOUS ISTAROXIME FOR THE TREATMENT OF ACUTE HEART FAILURE | WINDTREE THERAPEUTICS, INC. (US) | 2024-09-05 | — | — | US | disclosed |
| CN-110114066-B | Ophthalmic medicine containing salbutamol | 拉乌夫·雷基克 | 2023-06-27 | — | — | CN | disclosed |
| US-20230139837-A1 | Photo-Cleavable Surfactants | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-05-04 | — | — | US | disclosed |
| US-11567085-B2 | Photo-cleavable surfactants | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-11484513-B2 | Salbutamol-containing ophthalmic medicament | REKIK RAOUF (TN) | 2022-11-01 | — | — | US | disclosed |
| WO-2022159678-A9 | INTRAVENOUS ISTAROXIME FOR THE TREATMENT OF ACUTE HEART FAILURE | WINDTREE THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| WO-2022159678-A1 | INTRAVENOUS ISTAROXIME FOR THE TREATMENT OF ACUTE HEART FAILURE | WINDTREE THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20210253519-A1 | Photo-Cleavable Surfactants | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-08-19 | — | — | US | disclosed |
| CN-111110689-B | Pharmaceutical composition and pharmaceutical preparation for promoting blood circulation, removing blood stasis, dredging collaterals and relieving pain | 吉林修正药业新药开发有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20190160027-A1 | SALBUTAMOL-CONTAINING OPHTHALMIC MEDICAMENT | REKIK RAOUF (TN) | 2019-05-30 | — | — | US | disclosed |
| US-20100137232-A1 | COMPOSITION COMPRISING A DIURETIC AND A CARDIAC GLYCOSIDE FOR THE TREATMENT OF DNA VIRAL INFECTIONS OF THE EYE | HENDERSON MORLEY PLC (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20070219142-A1 | Composition Comprising a Diuretic and/or Cardiac Glycosed for the Treatment of Dna Viral Infections of the Eye | HENDERSON MORLEY PLC (GB) | 2007-09-20 | — | — | US | disclosed |
| EP-1742638-A1 | COMPOSITION COMPRISING A DIURETIC AND/OR CARDIAC GLYCOSIDE FOR THE TREATMENT OF DNA VIRAL INFECTIONS OF THE EYE | Henderson Morley Plc (GB) | 2007-01-17 | — | — | EP | disclosed |
| CN-1761680-A | Metastin derivative and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-04-19 | — | — | CN | disclosed |
| WO-2005102351-A1 | COMPOSITION COMPRISING A DIURETIC AND/OR CARDIAC GLYCOSIDE FOR THE TREATMENT OF DNA VIRAL INFECTIONS OF THE EYE | HENDERSON MORLEY PLC (GB) | 2005-11-03 | — | — | WO | disclosed |
| EP-1523550-A2 | IMMORTALIZED COLON EPITHELIAL CELLS AND THE USE THEREOF | Universität Potsdam (DE) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004011629-A2 | IMMORTALIZED COLON EPITHELIAL CELLS AND THE USE THEREOF | UNIVERSITÄT POTSDAM (DE) | 2004-02-05 | — | — | WO | disclosed |
| EP-1179540-A1 | NOVEL POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2002-02-13 | — | — | EP | disclosed |
| WO-1992007566-A2 | ANTIFUNGAL ACTIVITY OF AND PREVENTION OF DRUG INDUCED NEPHROTOXICITY BY METHYLXANTHINE ANALOGUES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160027-A1 | SALBUTAMOL-CONTAINING OPHTHALMIC MEDICAMENT | ADRB3, ADRB2, ADRB1 | P2RY1 150/4885P2RY2 140/4885P2RY11 260/4885 |
| US-11484513-B2 | Salbutamol-containing ophthalmic medicament | ADRB3, ADRB2, ADRB1 | P2RY1 150/4885P2RY2 140/4885P2RY11 260/4885 |
| US-12304884-B2 | Photo-cleavable surfactants | PTMS, PRSS1, SRMS | P2RY1 3851/4885P2RY2 3802/4885P2RY11 2912/4885 |
| US-20240293426-A1 | INTRAVENOUS ISTAROXIME FOR THE TREATMENT OF ACUTE HEART FAILURE | TNNI3, TNNT2, TNNC1 | P2RY1 2328/4885P2RY2 1727/4885P2RY11 651/4885 |
| US-11567085-B2 | Photo-cleavable surfactants | PTMS, PRSS1, SRMS | P2RY1 3851/4885P2RY2 3802/4885P2RY11 2912/4885 |
| US-20230139837-A1 | Photo-Cleavable Surfactants | PTMS, PRSS1, SRMS | P2RY1 3851/4885P2RY2 3802/4885P2RY11 2912/4885 |
| US-20210253519-A1 | Photo-Cleavable Surfactants | PTMS, PRSS1, TMPRSS4 | P2RY1 4078/4885P2RY2 3974/4885P2RY11 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.